drugset / Trial / NCT06568731

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

NCT06568731

Phase 1 Completed 23 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danuglipron The total number of weeks of the study is about 15 (about 4 months).

Timeline

Start
2024-08-23
Primary completion
2024-12-18
Completion
2024-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Danuglipron Small molecule Oral

Indications